2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.65

PP01.65 - Zhe Lei

Pdf Summary

Lung cancer remains the leading cause of cancer-related deaths in China, with low survival rates attributed to tumor metastasis facilitated by the epithelial-mesenchymal transition (EMT). This study focuses on the role of ZMIZ2, a transcriptional co-factor, in the progression of lung adenocarcinoma (LUAD) metastasis through its impact on EMT. The study aims to illuminate the potential of ZMIZ2 as a therapeutic target for LUAD treatment.<br /><br />Immunohistochemical assays were used to detect protein levels of ZMIZ2, and RNA sequencing was conducted to analyze differentially expressed genes in H1299 cells overexpressing ZMIZ2. Results indicate that ZMIZ2 overexpression correlates with poor prognosis in LUAD patients and promotes cancer cell proliferation, migration, invasion, and EMT. This overexpression activates the PI3K/AKT signaling pathway, which is crucial for LUAD cell metastasis and proliferation.<br /><br />These findings suggest that ZMIZ2 is a significant molecular player in LUAD, offering a novel therapeutic target for treatment. Targeting ZMIZ2 could potentially disrupt the activation of the AKT signaling pathway, inhibiting LUAD metastasis and improving patient outcomes. The study highlights the necessity of further research into ZMIZ2's mechanisms, with therapeutic interventions potentially benefiting LUAD patients through more targeted, effective treatment strategies.

Keywords

lung cancer

China

tumor metastasis

epithelial-mesenchymal transition

ZMIZ2

lung adenocarcinoma

therapeutic target

PI3K/AKT signaling pathway

cancer cell proliferation

RNA sequencing